Analyst consensus rating
Janux Therapeutics Analyst Rating: Strong Buy
JANX is rated Strong Buy by 17 analysts with a $36.24 target. As of 2026-08-26.
Direct answer
Janux Therapeutics's consensus rating is Strong Buy.
17 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $36.24.
Forecast evidence checked August 26, 2026.
Get free Janux Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $18.68
- Average price target
- $36.24
- High price target
- $75.00
- Low price target
- $14.00
- Low target gap
- -25.1%
- Target upside
- +94%
- High target gap
- +301.5%
- Target range width
- 326.6%
- Consensus rating
- Strong Buy
- Analysts
- 17
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Janux Therapeutics?
Janux Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $36.24.
How far are Janux Therapeutics's low and high targets from the recorded price?
The low target implies -25.1%, while the high target implies +301.5%.
How many analysts are included in Janux Therapeutics's consensus?
The verified consensus includes 17 analysts.
How is Janux Therapeutics's target upside or downside calculated?
The average target of $36.24 is divided by the recorded price of $18.68, then one is subtracted to produce +94%. This does not guarantee a future return.
When was Janux Therapeutics's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.